Trial Profile
Safety of a Novel Meningococcal Group B Vaccine Used in Response To Two Outbreaks in the US
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 Oct 2015
Price :
$35
*
At a glance
- Drugs Meningococcal-vaccine-group-B-OMV-GlaxoSmithKline/Finlay (Primary)
- Indications Meningococcal group B infections
- Focus Adverse reactions; Expanded access
- 09 Oct 2015 New trial record
- 26 Aug 2015 Results presented at the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management.